VANCOUVER, BRITISH COLUMBIA / TheNewswire / October 6, 2017 - the board of directors of BioHEP Technologies Ltd. (the “Company”) announces that the transaction contemplated in the Assignment and Assumption Agreement dated for reference April 21, 2017, between BioDE Ventures Ltd. (“BioDE”) and the Company (the “Assignment Agreement”), previously announced on May 3, 2017 have closed.

Pursuant to the Assignment Agreement, BioDE (now known as Exro Technologies Inc.) assigned to the Company a license agreement and certain patents for the price of $450,000 which was paid by the Company by issuing 448,321 shares of the Company to BioDE at a deemed value of $1.00 per share and cash consideration of approximately $1,679.

An independent valuation consultant was retained to confirm the fair value of the License Agreement and the Patents.  The value of the shares of the Company was determined by dividing the value of the main assets of the Company by the number of issued and outstanding shares of the Company.

ON BEHALF OF THE BOARD OF DIRECTORS

Chester Shynkaryk

Chief Executive Officer

BioDE Ventures Ltd.

Tel: (604) 722-9140